Lilly's $2.9B deal adds treatments for Graves' disease and food allergies
Eli Lilly is acquiring Merida Biosciences for about $2.88 billion in cash, expanding its immunology and allergic-disease pipeline beyond its obesity drugs, with the deal expected to close in Q4 2026 and marking Lilly’s ongoing aggressive M&A strategy. Merida’s lead program MER511 targets Graves’ disease and thyroid eye disease, while MER769 is in preclinical development for food allergy, asthma and chronic spontaneous urticaria, underscoring a broadened portfolio as Lilly references roughly $29 billion in upfront and milestone payments this year across acquisitions.
Business · 12 sources · Sep 9, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Merida Bikes
Merida Industry Co., Ltd is a Taiwan-based company with R&D headquarters in Germany that designs, manufactures, and markets bicycles globally in over 77 countries. Founded in 1972 by Ike Tseng (1932–2012), the company designs and manufactures over two million bicycles a year at its factories in Taiwan, China, and Germany. After Tseng's death in January 2012, his son Michael Tseng became the company's president.
Everything about Merida Bikes →- Headquarters
- Yuanlin City
- Inception
- 1972
- Website
- http://www.merida-bikes.com/